Nexviadyme is an enzyme replacement therapy used to treat patients with Pompe disease, a rare inherited disorder caused by the lack of an enzyme called alpha-glucosidase. Patients with Pompe disease have a build-up of glycogen (complex sugars) in body tissues, including the heart, lung and skeletal muscles, causing enlarged heart, breathing difficulties and muscle weakness. Nexviadyme contains the active substance avalglucosidase alfa.
Therapeutic Indication
### Therapeutic indication Nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid ?-glucosidase deficiency).
Therapeutic Area (MeSH)
N/AATC Code
A16
ATC Item
其它消化道和代谢药物
Pharmacotherapeutic Group
Other alimentary tract and metabolism products
Active Substance (Summary)
INN / Common Names
N/AEMA Name
Nexviadyme
Medicine Name
Nexviadyme
Aliases
N/ANo risk management plan link.
